Paper No. 8
`Date Filed: June 24, 2016
`
`Filed on behalf of: Aventis Pharma S.A.
`
`By:
`
`Dominick A. Conde
`dconde@fchs.com
`(212) 218-2100
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`________________
`
`MYLAN LABORATORIES LIMITED
`Petitioner,
`v.
`AVENTIS PHARMA S.A.
`Patent Owner.
`________________
`
`Case IPR2016-00712
`U.S. Patent No. 8,927,592
`________________
`
`PATENT OWNER’S EXHIBIT LIST 1
`
`
`Date Filed: June 24, 2016
`
`Filed on behalf of: Aventis Pharma S.A.
`
`By:
`
`Dominick A. Conde
`dconde@fchs.com
`(212) 218-2100
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`________________
`
`MYLAN LABORATORIES LIMITED
`Petitioner,
`v.
`AVENTIS PHARMA S.A.
`Patent Owner.
`________________
`
`Case IPR2016-00712
`U.S. Patent No. 8,927,592
`________________
`
`PATENT OWNER’S EXHIBIT LIST 1
`
`
`
`Aventis
`Exhibit No.
`
`2001
`
`2002
`
`2003
`
`EXHIBIT LIST 1
`
`Description
`
`June 23, 2016 Declaration of Dr. Oliver Sartor.
`
`Curriculum Vitae of Dr. Oliver Sartor.
`
`A Randomized, Open Label, Phase 3 Study of Larotaxel IV every 3
`
`Weeks Versus Capecitabine (Xeloda) Tablets Twice Daily for 2
`
`Weeks in 3-Week Cycles in Patients with Metastatic Cancer (MBC)
`
`Progressing After Taxanes and Anthracycline Therapy (EFC6089),
`
`available at EFC6089_summary.pdf.
`
`2004
`
`Antonarakis & Eisenberger, Phase III Trials with Docetaxel-Based
`
`Combinations for Metastatic Castration-Resistant Prostate Cancer:
`
`Time to Learn From Past Experiences, 31(14) J. Clin. Oncol. 1709-
`
`12 (2013).
`
`2005
`
`Armstrong & George, New Drug Development in Metastatic
`
`Prostate Cancer, 26(4) Urologic Oncol.: Seminars & Original
`
`Investigations 430-37 (2008).
`
`2006
`
`Beer et al., Double-Blinded Randomized Study of High-Dose
`
`Calcitriol plus Docetaxel Compared with Placebo plus Docetaxel
`
`1
`
`
`
`in Androgen-Independent Prostate Cancer: A Report from the
`
`ASCENT Investigators, 25(6) J. Clin. Oncol. 669-74 (2007).
`
`2007
`
`Berry et al., Phase III Study of Mitoxantrone plus Low Dose
`
`Prednisone Versus Low Dose Prednisone Alone in Patients with
`
`Asymptomatic Hormone Refractory Prostate Cancer, 168(6) J.
`
`Urol. 2439-43 (2002).
`
`2008
`
`Bristol-Myers Squibb Reports Results for Phase 3 Trial of Yervoy®
`
`(Ipilimumab) in Previously-Treated Castration Resistant Prostate
`
`Cancer, Business Wire News HQ Press Release (September 12,
`
`2013), available at http://news.bms.com/press-release/rd-
`
`news/Bristol-myers-squibb-reports-results-Phase-3- trial-yervoy-
`
`ipilimumab-previousl.
`
`2009
`
`Cabral, Factors Determining Cellular Mechanisms of Resistance to
`
`Antimitotic Drugs, 4(1) Drug Resistance Updates 3-8 (2001).
`
`2010
`
`Carducci et al., A Phase 3 Randomized Controlled Trial of the
`
`Efficacy and Safety of Atrasentan in Men with Metastatic Hormone-
`
`Refractory Prostate Cancer, 110(9) Cancer 1959-66 (2007).
`
`2011
`
`D'Amico, US Food and Drug Administration Approval of Drugs for
`
`the Treatment of Prostate Cancer: A New Era Has Begun, 32(4) J.
`
`Clin. Oncol. 362-64 (2014).
`
`2
`
`
`
`2012
`
`2013
`
`2014
`
`December 2013 Yervoy® Label.
`
`Didier, US Patent Application Publication No. 2005/0065138.
`
`Di Lorenzo et al., Combination of Bevacizumab and Docetaxel in
`
`Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A
`
`Phase 2 Study, 54(5) Eur. Urol. 1089-96 (2008).
`
`2015
`
`Dieras et al., Phase II Multicenter Study of Larotaxel (XRP9881), a
`
`Novel Taxoid, in Patients with Metastatic Breast Cancer Who
`
`Previously Received Taxane-Based Therapy, 19(7) Annals of
`
`Oncol. 1255-60 (2008).
`
`2016
`
`Dumontet & Sikic, Mechanisms of Action of and Resistance to
`
`Antitubulin Agents: Microtubule Dynamics, Drug Transport, and
`
`Cell Death, 17(3) J. Clin. Oncol. 1061-70 (1999).
`
`2017
`
`Halabi et al., Prostate-Specific Antigen Changes as Surrogate for
`
`Overall Survival in Men with Metastatic Castration-Resistant
`
`Prostate Cancer Treated with Second-Line Chemotherapy, 31(31)
`
`J. Clin. Oncol. 1-9 (2013).
`
`2018
`
`Higano et al., Phase 1/2 Dose-Escalation Study of a GM-CSF-
`
`Secreting, Allogeneic, Cellular Immunotherapy for Metastatic
`
`Hormone-Refractory Prostate Cancer, 113(5) Cancer 975-84
`
`(2008).
`
`3
`
`
`
`2019
`
`2020
`
`July 2009 Avastin® Label.
`
`Kaur et al., Suramin 's Development: What Did We Learn?, 20(2)
`
`Investigational New Drugs 209-19 (2002).
`
`2021
`
`Kola & Landis, Can the Pharmaceutical Industry Reduce Attrition
`
`Rates?, 3(8) Nature Reviews Drug Discovery 711-15 (2004).
`
`2022
`
`Larotaxel Every 3 Weeks vs. Capecitabine in Patients with
`
`Metastatic Breast Cancer Progressing After Taxanes and
`
`Anthracycline Therapy, available at
`
`https://clinicaltrials.gov/ct2/show/NCT00081796?term
`
`=larotaxel&rank=7.
`
`2023
`
`Larotaxel plus Cisplatin vs. Gemcitabine plus Cisplatin in First
`
`Line Treatment of Patients with Locally Advanced/Metastatic
`
`Bladder Cancer, available at
`
`https://clinicaltrials.gov/ct2/show/NCT00625664?term=larotaxel&r
`
`ank=4.
`
`2024
`
`Larotaxel vs. 5-FU in Patients with Pancreatic Cancer Previously
`
`Treated with Gemcitabine, available at
`
`https://clinicaltrials.gov/ct2/show/NCT00417209?term=larotaxel&r
`
`ank=2
`
`2025
`
`Mackinnon et al., Molecular Biology Underlying the Clinical
`
`4
`
`
`
`Heterogeneity of Prostate Cancer: An Update, 133(7) Arch. Pathol.
`
`Lab. Med. 1033-40 (2009).
`
`2026
`
`Michaelson et al., Randomized, Placebo-Controlled, Phase III Trial
`
`of Sunitinib plus Prednisone Versus Prednisone Alone in
`
`Progressive Metastatic, Castration-Resistant Prostate Cancer,
`
`32(2) J. Clin. Oncol. 76-83 (2014).
`
`2027
`
`Mulcahy, Phase 3 Trial of Immunotherapy for Metastatic Prostate
`
`Cancer Terminated, Medscape (October 17, 2008), available at
`
`http://www.medscape.com/viewarticle/582220_print.
`
`2028
`
`Novacea, Inc. SEC Form 8-K at 1.02 (April 4, 2008), available at
`
`http://www.sec. gov/Archives/edgar/data/1178711/
`
`000119312508077953/d8k.htm.
`
`2029
`
`OncoGenex Announces Top-Line Survival Results of Phase 3
`
`SYNERGY Trial Evaluating Custirsen for Metastatic Castrate-
`
`Resistant Prostate Cancer, Acquire Media Press Release (April 28,
`
`2014), available at http://ir.oncogenex.com/releasedetail.cfm
`
`?ReleaseID=842949.
`
`2030
`
`Ramiah et al., Clinical Endpoints for Drug Development in
`
`Prostate Cancer, 18(3) Curr. Opin. Urol. 303-08 (2008).
`
`2031
`
`Roche Provides Update on Phase III study of Avastin in Men with
`
`5
`
`
`
`Late Stage Prostate Cancer, Media Release (March 12, 2010),
`
`http://www.roche.com/media/media_releases/med-cor-2010-03-
`
`12.htm.
`
`2032
`
`Satraplatin in Hormone Refractory Prostate Cancer Patients
`
`Previously Treated with One Cytotoxic Chemotherapy Regimen,
`
`available at https://clinicaltrials.gov/ct2/show/NCT00069745
`
`?term=SPARC&cond=prostate&rank=3.
`
`2033
`
`Slovin et al., Ipilimumab Alone or in Combination with
`
`Radiotherapy in Metastatic Castration-Resistant Prostate Cancer:
`
`Results from an Open-Label, Multicenter Phase I/II Study, 24(7)
`
`Annals of Oncol. 1813-21 (2013).
`
`2034
`
`Small et al., Granulocyte Macrophage Colony-Stimulating Factor
`
`Secreting Allogeneic Cellular Immunotherapy for Hormone-
`
`Refractory Prostate Cancer, 13(13) Clin. Cancer Res. 3883-91
`
`(2007).
`
`2035
`
`Small et al., Randomized Phase II Study Comparing 4 Monthly
`
`Doses of Ipilimumab (MDX-010) as a Single Agent or in
`
`Combination with a Single Dose of Docetaxel in Patients with
`
`Hormone-Refractory Prostate Cancer, 24(18S) J. Clin. Oncol.
`
`(Meeting Abstracts) S4609 (June 2006).
`
`6
`
`
`
`2036
`
`Sternberg et al., Larotaxel with Cisplatin in the First-Line
`
`Treatment of Locally Advanced/Metastatic Urothelial Tract or
`
`Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial
`
`(CILAB), 85(4) Oncology 208-15 (2013).
`
`2037
`
`Susman, ASCO: Calcitriol Fails in ASCENT-2 Prostate CA Trial,
`
`MedPage Today (June 9, 2010), available at
`
`http://www.medpagetoday.com/MeetingCoverage/ASCO/20575.
`
`2038
`
`Takeda Announces Termination of Orteronel (TAK-700)
`
`Development for Prostate Cancer in Japan, U.S.A. and Europe,
`
`Takeda Latest News Release (June 19, 2014), available at
`
`http://www.takeda.com/news/2014/20140619_6615.html.
`
`2039
`
`2040
`
`Gupta, US Patent Application Publication No. 2012/0301425.
`
`Van Cutsem et al., A Phase III Study Comparing Larotaxel to 5-FU
`
`(Continuous Intravenous 5-FU or Capecitabine) in Patients with
`
`Advanced Pancreatic Cancer (APC) Previously Treated with a
`
`Gemcitabine Containing Regimen, 21(6S) Annals of Oncol. Oral
`
`Presentations 0-007 (July 2010).
`
`2041
`
`Van Hook et al., Orteronel for the Treatment of Prostate Cancer,
`
`10(5) Future Oncol. 803-11 (2014).
`
`2042
`
`Wiechec & Hansen, The Effect of Genetic Variability on Drug
`
`7
`
`
`
`Response in Conventional Breast Cancer Treatment, 625 Eur. J.
`
`Pharmacol. 122-30 (2009).
`
`2043
`
`Williams, Discontinued Drugs in 2008: Oncology Drugs, 18(11)
`
`Expert Opin. Investig. Drugs 1581-94 (2009).
`
`2044
`
`Wirth & Froschermaier, The Antiandrogen Withdrawal Syndrome,
`
`25 (Suppl. 2) Urol. Res. S67-71(1997).
`
`2045
`
`Zatloukal et al., Randomized Multicenter Phase II Study of
`
`Larotaxel (XRP9881) in Combination with Cisplatin or
`
`Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage
`
`IIIB or Stage IV Non-Small Cell Lung Cancer, 3(8) J. Thorac.
`
`Oncol. 894-901 (2008).
`
`2046
`
`Zielinski & Chi, Custirsen (OGX-01 I): A Second-Generation
`
`Antisense Inhibitor of Clusterin in Development for the Treatment
`
`of Prostate Cancer, 8(10) Future Oncol. 1239-51 (2012).
`
`American Cancer Society, Cancer Facts & Figures 2009.
`
`Baselga et al., Phase II Study of Efficacy, Safety, and
`
`2047
`
`2048
`
`Pharmacokinetics of Trastuzumab Monotherapy Administered on a
`
`3-Weekly Schedule, 23(10) J. Clin. Oncol. 2162-71 (2005).
`
`2049
`
`Baselga et al., Phase II Study of Weekly Intravenous Trastuzumab
`
`8
`
`
`
`(Herceptin) in Patients with HER2/neu-Overexpressing Metastatic
`
`Breast Cancer, 26 (4 Suppl. 12) Semin. Oncol. 78-83 (1999).
`
`2050
`
`Bissery et al., Experimental Antitumor Activity of Taxotere (RP
`
`56976, NSC 628503), a Taxol Analogue, 51(18) Cancer Res. 4845-
`
`52 (1991).
`
`2051
`
`Chen et al., Gefitinib Treatment is Highly Effective in Non-Small-
`
`Cell Lung Cancer Patients Failing Previous Chemotherapy in
`
`Taiwan: A Prospective Phase II Study, 17(6) J. Chemother. 679-84
`
`(2005).
`
`2052
`
`Cisternino et al., Nonlinear Accumulation in the Brain of the New
`
`Taxoid TXD258 Following Saturation of P-glycoprotein at the
`
`Blood-Brain Barrier in Mice and Rats, 138(7) Br. J. Pharmacol.
`
`1367-75 (2003).
`
`2053
`
`Cobleigh et al., Multinational Study of the Efficacy and Safety of
`
`Humanized Anti-HER2 Monoclonal Antibody in Women who have
`
`HER2-Overexpressing Metastatic Breast Cancer that has
`
`Progressed After Chemotherapy for Metastatic Disease, 17(9) J.
`
`Clin. Oncol. 2639-48 (1999).
`
`2054
`
`De Bono et al., Open-Label Phase II Study Evaluating the Efficacy
`
`9
`
`
`
`and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-
`
`Naive Patients with Hormone-Refractory Prostate Cancer, 25(3) J.
`
`Clin. Oncol. 257-62 (2007).
`
`2055
`
`De Bono et al., Prednisone plus Cabazitaxel or Mitoxantrone for
`
`Metastatic Castration-Resistant Prostate Cancer Progressing after
`
`Docetaxel Treatment: a Randomized Open-Label Trial, 376(9747)
`
`Lancet 1147-54 (2010).
`
`2056
`
`European Medicine Agency, ICH Topic E8 General Considerations
`
`for Clinical Trials (March 1998).
`
`2057
`
`62(247) Federal Register 67377-388 (December 24, 1997), FDA
`
`Notice International Conference on Harmonisation; Guidance on
`
`Impurities: Residual Solvents.
`
`2058
`
`FDA News Release, FDA Approves New Indication for Taxotere -
`
`Prostate Cancer (May 19, 2004).
`
`2059
`
`FDA News Release, FDA Approves New Treatment for Advanced
`
`Prostate Cancer (June 17, 2010).
`
`2060
`
`Fukuoka et al., Multi Institutional Randomized Phase II Trial of
`
`Gefitinib for Previously Treated Patients with Advanced Non–
`
`Small-Cell Lung Cancer, 21(12) J. Clin. Oncol. 2237-46 (2003).
`
`10
`
`
`
`2061
`
`Gianni et al., Nonlinear Pharmacokinetics and Metabolism of
`
`Paclitaxel and Its Pharmacokinetic/Pharmacodynamic
`
`Relationships in Humans, 13(1) J. Clin. Oncol. 180-90 (1995).
`
`2062
`
`Hande, The Importance of Drug Scheduling in Cancer
`
`Chemotherapy: Etoposide as an Example, 1(4) The Oncologist
`
`2063
`
`2064
`
`2065
`
`2066
`
`2067
`
`2068
`
`234-29 (1996).
`
`January 2008 Herceptin® Label.
`
`Hope, ‘Last Hope’ Drug for Prostate Cancer Patients Is Axed from
`
`the NHS, in a Move Doctors Call a Travesty, DailMail.com
`
`(January 9, 2015), available at
`
`http://www.dailymail.co.uk/health/article-2903235/Last-hope-drug-
`
`prostate-cancer-patients-axed-NHS-dcotors-call-travesty.html.
`
`July 2004 Iressa® Label.
`
`October 2007 Ixempra® Label.
`
`June 2015 Jevtana® Label.
`
`Sanofi-Aventis Press Release, Phase III Data Showing Improved
`
`Survival with Jevtana® (cabazitaxel) Injection in Second-Line
`
`Advanced Prostate Cancer Published in the Lancet (October 1,
`
`2010).
`
`11
`
`
`
`2069
`
`Water Insoluble Drug Formulation 213, 267-68, 355, 393-94, 427,
`
`436, 645, 650 (First Edition, Liu ed. 2000).
`
`2070
`
`Lokich & Anderson, Dose Intensity for Bolus Versus Infusion
`
`Chemotherapy Administration: Review of the Literature for 27
`
`Anti-Neoplastic Agents, 8(1) Ann Oncol. 15-25 (1997).
`
`2071
`
`Malhotra et al., Cabazitaxel: a Novel Drug for Hormone-
`
`Refractory Prostate Cancer, 13(2) Mini Revs. Med. Chem. 1-6
`
`(2013).
`
`2072
`
`Excerpt of Claim Construction Hearing Transcript from Sanofi-
`
`Aventis U.S., LLC et al. v. Mylan Laboratories Ltd., et al., 3:15-cv-
`
`03392(MAS)(LHG).
`
`2073
`
`Mokbel, Concise Notes in Oncology for MRCP and MRCS, 6-7
`
`(2005).
`
`2074
`
`Morant et al., Capecitabine in Hormone-Resistant Metastatic
`
`Prostatic Carcinoma – a Phase II Trial, 90(7) Br. J. Cancer 1312–
`
`17 (2004).
`
`2075
`
`Motzer et al., Activity of SU11248, a Multitargeted Inhibitor of
`
`Vascular Endothelial Growth Factor Receptor and Platelet-
`
`Derived Growth Factor Receptor, in Patients with Metastatic Renal
`
`Cell Carcinoma, 24(1) J. Clin. Oncol. 16-24 (2006).
`
`12
`
`
`
`2076
`
`NCCN Clinical Practice Guidelines in Oncology: Breast Cancer
`
`V.1.2009.
`
`2077
`
`NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer
`
`V.2.2009.
`
`2078
`
`National Horizon Scanning Centre, Cabazitaxel (XRP-6258) for
`
`Hormone Refractory, Metastatic Prostate Cancer – Second Line
`
`After Docetaxel (April 2009).
`
`2079
`
`Niho et al., First-Line Single Agent Treatment with Gefitinib in
`
`Patients with Advanced Non–Small-Cell Lung Cancer: A Phase II
`
`Study, 24(1) J. Clin. Oncol. 64-69 (2006).
`
`2080
`
`Pazdur, Endpoints for Assessing Drug Activity in Clinical Trials,
`
`13(suppl 2) The Oncologist 19-21 (2008).
`
`2081
`
`Perez-Soler et al., Determinants of Tumor Response and Survival
`
`with Erlotinib in Patients with Non–Small-Cell Lung Cancer,
`
`2082
`
`2083
`
`22(16) J. Clin. Oncol. 3238-47 (2004).
`
`June 2012 Perjeta® Label.
`
`Pienta & Smith, Advances in Prostate Cancer Chemotherapy: A
`
`New Era Begins, 55(5) CA Cancer J. Clin. 300-18 (2005).
`
`2084
`
`Ramanathan et al., A Phase II Study of Milataxel: a Novel Taxane
`
`13
`
`
`
`Analogue in Previously Treated Patients with Advanced Colorectal
`
`Cancer, 61(3) Cancer Chemother. Pharmacol. 453-58 (2008).
`
`2085
`
`Reck et al., An Open-Label, Multi Centre, Phase II, Non-
`
`Comparative Trial of ZD1839 Monotherapy in Chemotherapy-
`
`Naive Patients with Stage IV or Stage III Non-Operable Non-Small
`
`Cell Lung Cancer (NSCLC), 23(16S) J. Clin. Oncol. 7098 (2005).
`
`2086
`
`Sanofi-Aventis U.S., LLC et al. v. Mylan Laboratories Ltd., et al.,
`
`3:15-cv-03392(MAS)(LHG), Excerpts of Defendants’ Joint
`
`Responsive Claim Construction Brief.
`
`2087
`
`Compilation of excerpts of SEC 20-F filings showing Jevtana®
`
`sales.
`
`2088
`
`Spigel et al., Single-Agent Gefitinib in Patients with Untreated
`
`Advanced Non-Small-Cell Lung Cancer and Poor Performance
`
`Status: A Minnie Pearl Cancer Research Network Phase II Trial,
`
`7(2) Clin. Lung Cancer 127-32 (2005).
`
`2089
`
`Straub et al., Intravenous Hydrophobic Drug Delivery: A Porous
`
`Particle Formulation of Paclitaxel (AI-850), 22(3) Pharm Res. 347-
`
`55 (2005).
`
`2090
`
`April 2008 Sutent® Label.
`
`14
`
`
`
`2091
`
`Takeda et al., The Establishment of Two Paclitaxel-Resistant
`
`Prostate Cancer Cell Lines and the Mechanisms of Paclitaxel
`
`Resistance with Two Cell Lines, 67(9) The Prostate 955-67 (2007).
`
`2092
`
`2093
`
`2094
`
`April 2009 Tarceva® Label.
`
`February 2000 Taxol® Label.
`
`Ten Tije et al., Pharmacological Effects of Formulation Vehicles:
`
`Implications for Cancer Chemotherapy, 42(7) Clin. Pharmacokinet.
`
`665-85 (2003).
`
`2095
`
`Vogel et al., Efficacy and Safety of Trastuzumab as a Single Agent
`
`in First-Line Treatment of HER2-Overexpressing Metastatic Breast
`
`Cancer, 20(3) J. Clin. Oncol. 719-26 (2002).
`
`2096
`
`Vrignaud et al., Preclinical Antitumor Activity of Cabazitaxel, a
`
`Semisynthetic Taxane Active in Taxane-Resistant Tumors, 19(11)
`
`2097
`
`2098
`
`2099
`
`Clin. Cancer Res. 2973-83 (2013).
`
`Reserved.
`
`February 2003 Xeloda® Label.
`
`Ziada et al., The Use of Trastuzumab in the Treatment of Hormone
`
`Refractory Prostate Cancer; Phase II Trial, 60(4) The Prostate
`
`332-37 (2004).
`
`15
`
`
`
`2100
`
`2006 clinicaltrials.gov listing for TROPIC: View of NCT00417079
`
`on 2006_12_28, available at http://clinicaltrials.gov/archive?
`
`NCT00417079/2006_12_28.
`
`2101
`
`Dieras et al., Larotaxel (L) in Combination with Trastuzumab in
`
`Patients with Her2+ Metastatic Breast Cancer (MBC): Interim
`
`Analysis of an Open Phase II Label Study, 26(15S) J. Clin. Oncol.
`
`1070 (2008).
`
`2102
`
`Excerpts of Sanofi-Aventis SEC Form 20-F (December 31, 2006),
`
`available at https://www.sec.gov/Archives/edgar/data/1121404/
`
`000119312507072848/d20f.htm.
`
`2103
`
`Butler, Natural Products to Drugs: Natural Product-Derived
`
`Compounds in Clinical Trials, 25(3) Nat. Prod. Rep. 475-516
`
`(2008).
`
`2104
`
`Canil et al., Randomized Phase II Study of Two Doses of Gefitinib
`
`in Hormone-Refractory Prostate Cancer: A Trial of the National
`
`Cancer Institute of Canada –Clinical Trial Group, 23(3) J. Clin.
`
`Oncol. 455-60 (2005).
`
`2105
`
`Mononen et al., Two Percent of Finnish Prostate Cancer Patients
`
`Have a Germ-Line Mutation in the Hormone-Binding Domain of
`
`the Androgen Receptor Gene, 60(22) Cancer Research 6471-81
`
`16
`
`
`
`(2000).
`
`2106
`
`Saad et al., Randomized Phase II Trial of Custirsen (OGX-011) in
`
`Combination with Docetaxel or Mitoxantrone as Second-Line
`
`Therapy in Patients with Metastatic Castrate-Resistant Prostate
`
`Cancer Progressing After First-Line Docetaxel: CUOG Trial P-
`
`06c, 17(17) Clin. Cancer Res. 5765-73 (2011).
`
`2107
`
`Sonpavde et al., Sunitinib Malate for Metastatic Castration-
`
`Resistant Prostate Cancer Following Docetaxel-Based
`
`Chemotherapy, 21(2) Ann. Oncol. 319-24 (2010).
`
`2108
`
`Taylor et al., Integrative Genomic Profiling of Human Prostate
`
`Cancer, 18(1) Cancer Cell 1-23 (2010).
`
`2109
`
`Mubiru et al., Nonhuman Primates as Models for Studies of
`
`Prostate Specific Antigen and Prostatic Diseases, 68(14) Prostate
`
`1-16 (2008).
`
`2110
`
`Latif et al., Phase II Study of Oral Bis (Aceto) Ammine Dichloro
`
`(Cyclohexamine) Platinum (IV) (JM-216, BMS-182751) Given
`
`Daily x 5 in Hormone Refractory Prostate Cancer (HRPC), 23(1)
`
`Invest. New Drugs. 79-84 (2005).
`
`2111
`
`August 2008 Novantrone® Label.
`
`17
`
`
`
`2112
`
`Small et al., A Phase II Trial of Gefitinib in Patients with Non-
`
`Metastatic Hormone-Refractory Prostate Cancer, 100(4) BJU Int’l
`
`765-69 (2007).
`
`2113
`
`Joffe et al., Quality of Informed Consent in Cancer Clinical Trials:
`
`A Cross-Sectional Survey, 358(9295) The Lancet 1772-77 (2001).
`
`June 24, 2016
`
`Respectfully submitted,
`
`/Dominick A. Conde/
`Dominick A. Conde (Reg. No. 33,856)
`FITZPATRICK, CELLA, HARPER & SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel: (212) 218-2100
`
`Attorney for Patent Owner,
`Aventis Pharma S.A.
`
`18
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e)(4), I certify that a copy of the foregoing
`
`PATENT OWNER’S EXHIBIT LIST 1 was served on June 24, 2016 by causing it
`
`to be sent by email to counsel for Petitioner at the following email addresses:
`
`sparmelee@wsgr.com
`
`mrosato@wsgr.com
`
`jmills@wsgr.com
`
`June 24, 2016
`
`Respectfully submitted,
`
`/Dominick A. Conde/
`Dominick A. Conde (Reg. No. 33,856)
`FITZPATRICK, CELLA, HARPER & SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel: (212) 218-2100
`
`19
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
